SLC5A2 and acute kidney injury: The meta-analysis results confirmed a protective association between SGLT2 inhibitor therapy and AKI risk reduction (odds ratio (OR) = 0.525, 95% confidence interval (CI) 0.437-0.631; <i>p</i> < 0.001).<h4>Conclusion</h4>In this study, SGLT2 inhibitor administration was associated with a decreased incidence of postoperative AKI in OPCABG patients.<h4>Clinical trial registration</h4>NCT05888168, https://clinicaltrials.gov/study/NCT05888168?cond=NCT05888168&rank=1.